Cytokinetics CEO Robert Blum sells $636,900 in stock By Investing.com
Cytokinetics CEO Robert Blum sold 7,500 shares of company stock worth approximately $636,900 on July 1, 2026, under a Rule 10b5-1 trading plan. Following this transaction, Mr. Blum directly holds 377,830 shares, while the company's stock trades near its 52-week high, having returned 148% over the past year. This comes amidst analyst upgrades and positive developments for its heart drug Myqorzo, which recently launched in Germany.
Cytokinetics CEO Robert Blum sells $636,900 in stock
Cytokinetics CEO Robert Blum sold 7,500 shares of the company's common stock for approximately $636,900 on July 1, 2026, under a Rule 10b5-1 trading plan. Following the sale, he directly holds 377,830 shares. The transaction occurs as Cytokinetics shares trade near their 52-week high, having returned 148% over the past year, though InvestingPro suggests the company may be overvalued.
CYTOKINETICS (NASDAQ: CYTK) CFO exercises options, sells 1,112 shares at $87.79
CYTOKINETICS (NASDAQ: CYTK) EVP and CFO Sung Lee reported exercising 1,112 non-qualified stock options at $48.51 per share and subsequently selling the same number of common shares at $87.79 per share in an open-market transaction. Following these transactions, Lee directly holds 63,221 shares of common stock, and 26,709 non-qualified stock options remain outstanding. This activity represents a net sale by share count, structured as an exercise-and-sell sequence.
Form 4 Cytokinetics Inc For: 2 July By Investing.com
Investing.com reports on a Form 4 filing for Cytokinetics Inc. on July 2nd. The article reiterates this information and provides general market data, including various stock market indices, commodity prices, bond yields, and trending stocks. It also features popular financial news stories and investment challenges.
Cytokinetics (NASDAQ: CYTK) EVP exercises options, sells 15,000 shares at $85.80
Andrew Callos, EVP of Cytokinetics (NASDAQ: CYTK), exercised options to acquire 15,000 shares of common stock at $23.26 per share and subsequently sold all 15,000 shares in an open-market transaction at an average price of $85.80 per share on July 1, 2026. Following these transactions, Callos directly owns 58,555 shares of common stock and retains 24,000 non-qualified stock options. This activity was reported in a Form 4 SEC filing, indicating a net sale of 15,000 shares valued at $1.29 million.
Cytokinetics (NASDAQ: CYTK) CEO trims stake with 7,500-share sale
Cytokinetics President & CEO Robert I. Blum sold 7,500 shares of CYTK common stock at $84.92 per share in an open-market transaction on July 1, 2026. Following the sale, Blum directly holds 377,830 shares, with an additional 2,083 shares each held indirectly by two irrevocable trusts. This transaction, detailed in a Form 4 SEC filing, represents a net sale of $636,900 and indicates a reduction in his direct holdings.
CYTK insider Robert Blum notifies planned sale of 44,990 shares (CYTK)
Robert Blum, an insider at Cytokinetics Inc. (CYTK), has filed a Form 144 to report planned sales of company stock, including 44,990 shares from stock option exercise and 7,510 shares from Restricted Stock Units. The filing also details several completed 10b5-1 sales of 7,500 shares each across April, May, and June 2026. These transactions are described as routine affiliate disclosures, with 10b5-1 plans indicating prearranged trading schedules.
Cytokinetics (CYTK) Is Up 6.5% After Myqorzo’s Early Commercial Uptake Signals Growing Clinical Interest – Has The Bull Case Changed?
Cytokinetics is seeing a 6.5% stock increase driven by the early commercial success of its heart drug, Myqorzo, which has received regulatory approvals in the US, Europe, and China. The early adoption by physicians and patients is validating the drug's potential, shifting the company's investment narrative from development-heavy to commercial. While this presents a positive shift, investors are cautioned to consider the company's persistent losses and the need for sustained Myqorzo prescription momentum to avoid further dilution.
Cytokinetics Inc stock hits 52-week high at $88.00
Cytokinetics Inc (CYTK) stock reached a new 52-week high of $88.00, marking a significant 159.39% increase over the past year due to substantial revenue growth and positive analyst sentiment. The company's heart drug, Myqorzo, has seen a successful commercial launch in Germany and received upgraded ratings and price targets from UBS, Mizuho, and RBC Capital, projecting peak revenues of up to $5.7 billion. Despite trading above its Fair Value according to InvestingPro, these developments highlight strong investor confidence and growth prospects for Cytokinetics.
Cytokinetics Prepares for Commercial Rollout Following Regulatory Approvals Across Major Markets
Cytokinetics (CYTK) is transitioning from a development-stage biotech to a commercial business with the launch of its lead drug, MYQORZO, for obstructive hypertrophic cardiomyopathy in the U.S. and Europe. The drug has shown encouraging early sales and has received positive late-stage trial results for a related condition, non-obstructive HCM, which could expand its market. Despite early commercialization costs leading to a net loss, the company benefits from strong insurance coverage, additional heart disease drugs in development, and limited direct competition in its specific mechanism of action.
Cytokinetics(CYTK.US) Officer Sells US$3.19 Million in Common Stock
This article reports that Robert I. Blum, an officer at Cytokinetics (CYTK.US), sold 28,000 shares of common stock for a total of $3.19 million on June 28, 2026. Prior to this transaction, Blum directly owned 174,013 shares of the company. The sale reduced his direct ownership percentage from 0.05% to 0.04%.
Insider Sell Alert: EVP, Chief Financial Officer Sung Lee Sells Shares of Cytokinetics Inc (CYTK)
Sung Lee, EVP and CFO of Cytokinetics Inc (CYTK), sold 3,134 shares of the company on June 29, 2026, reducing his total holdings to 63,221 shares. This sale is part of a trend over the past year where insiders have sold 74 times with no insider buys. The stock is currently trading at $85, with a market cap of $11.847 billion, and is considered a "Possible Value Trap" based on its GF Value of $248.72.
Cytokinetics CFO Lee Sung sells $3.18m in company stock
Cytokinetics CFO Lee Sung sold 38,730 shares of the company's stock for approximately $3.18 million after exercising stock options. This transaction occurred as the company's shares traded near their 52-week high, and the stock is considered overvalued by InvestingPro analysis despite recent positive news regarding its heart drug Myqorzo and several analyst upgrades. Following the sale, Sung directly holds 63,221 shares.
Cytokinetics (CYTK) CFO sells 38,730 shares at $82.30 after exercising options
Cytokinetics' EVP and CFO Sung Lee engaged in an exercise-and-sell transaction, acquiring 38,730 shares through stock options at strike prices of $48.51 and $44.36, and subsequently selling all 38,730 shares at an average price of $82.30 per share. Following this transaction, Lee's direct ownership in Cytokinetics stands at 63,221 shares. The transaction, filed as a Form 4, indicates a net sale of $3.19 million.
Cytokinetics (NASDAQ: CYTK) CFO trades shares after option exercises
Cytokinetics (NASDAQ: CYTK) EVP and CFO Sung Lee engaged in an options exercise and share sale transaction on June 29, 2026. Lee exercised options to acquire 3,134 shares at strike prices of $44.36 and $48.51, and simultaneously sold these 3,134 shares on the open market at $85.00 per share. This activity is a common method for executives to monetize equity compensation.
Option exercise and 10b5-1 sales reported by CYTK (NASDAQ: CYTK)
CYTK filed a Form 144 reporting an exercise of stock options for 9,503 shares, settled for cash on June 29, 2026. The filing also detailed prior Rule 10b5-1 sales by Sung Lee, totaling 69,331 shares across three dates in May and June 2026, generating over $5.5 million. This activity reflects routine insider liquidity events and a scheduled trading plan.
CYTK Upgraded by UBS -- Price Target Raised to $115
UBS has upgraded Cytokinetics (CYTK) to a "Buy" rating, raising its price target to $115 from $69, signaling a potential upside of 66.67%. Despite this optimistic analyst view and the stock being significantly undervalued according to GuruFocus's GF Value, caution is advised due to the company's low GF Score™ in financial strength and profitability, coupled with recent insider selling of $13.7 million. Investors are encouraged to weigh these contrasting factors carefully.
Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?
This article summarizes a bullish thesis on Cytokinetics, Incorporated (CYTK) from TradersPro’s Substack, highlighting its transition to a commercial-stage biopharmaceutical company. CYTK's lead drug, Myqorzo, has received global regulatory approvals, showing early commercial success and expanding into new cardiac indications. The company benefits from favorable market dynamics, a differentiated mechanism of action, and increasing investor interest, positioning it for potential re-rating as its commercial execution de-risks.
Is Cytokinetics (CYTK) Still Cheap After Its Strong Share Price Run?
Cytokinetics (CYTK) has seen significant share price appreciation over the past year, currently trading at $82.19 against an analyst target of $105.60. While a narrative suggests it is 11.6% undervalued with a fair value of $92.94 due to an expanding market for its therapies and anticipated approvals, the company faces risks, including potential setbacks in late-stage trials. Investors are advised to look beyond headlines and examine underlying data regarding potential upsides and downsides.
Price to sales forward of Cytokinetics, Incorporated – SWB:KK3A
This article focuses on the "Price to sales forward" metric for Cytokinetics, Incorporated (SWB:KK3A) on the Stuttgart Stock Exchange. It appears to be a financial data page from TradingView, indicating that the market was closed with no trades when the data was accessed. The content suggests that detailed financial figures for this metric would typically be displayed in the "value," "change," and "change %" fields.
Enterprise value to EBIT forward of Cytokinetics, Incorporated – NASDAQ:CYTK
This page displays financial data for Cytokinetics, Incorporated (NASDAQ: CYTK), specifically its enterprise value to EBIT forward. It provides an overview of the company's financials on the TradingView platform. The content primarily focuses on presenting this specific financial metric for investors and analysts using their service.
Cytokinetics, Incorporated Actuals & Estimates (NASDAQ:CYTK)
This article provides an overview of Cytokinetics, Incorporated (NASDAQ: CYTK) stock, including its current price, market capitalization, and historical performance. It also details financial actuals and analyst estimates, such as earnings per share and revenue, and provides insights into future forecasts and upcoming earnings dates. The company's financials, employee count, and investment analysis are also discussed.
CYTK: Broker files Rule 144 after insider 10b5-1 sales (CYTK)
Morgan Stanley Smith Barney LLC has filed a Rule 144 notice for Cytokinetics Inc. (CYTK), detailing proposed sales of Common stock related to restricted stock units and previous 10b5-1 sales. The filing indicates 6,695 Restricted Stock Units are set to be sold with a date of May 31, 2026, and also records past sales by Sung Lee totaling 38,730 shares on June 24, 2026, for $3,187,328.11 and 23,906 shares on May 5, 2026, for $1,837,766.45. This regulatory disclosure provides transparency regarding insider stock transactions and upcoming share releases.
Cytokinetics, Incorporated Actuals & Estimates (HAM:KK3A)
This article provides an overview of Cytokinetics, Incorporated (HAM:KK3A) stock performance, actuals, and analyst estimates. It covers financial data, recent price movements, future forecasts, and key financial metrics like earnings, revenue, and market capitalization. The company's next earnings report is scheduled for July 30, 2026.
Price to earnings forward of Cytokinetics, Incorporated – NASDAQ:CYTK
The article focuses on the "Price to earnings forward" metric for Cytokinetics, Incorporated (NASDAQ: CYTK). It appears to be a financial data page from TradingView, indicating that the market for CYTK is currently closed.
Cytokinetics EVP Malik sells $278k in stock
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, sold 3,500 shares of company stock for approximately $278,285 after exercising non-qualified stock options. This transaction occurred while CYTOKINETICS shares were near their 52-week high, and Malik retains a substantial number of shares and derivative securities. The company recently completed a significant stock offering and launched its heart drug Myqorzo in Europe.
CYTK (NASDAQ) insider sale notice: 38,730 shares proposed on 06/24/2026
CYTK (Cytokinetics Inc.) has filed a Form 144 notice proposing the sale of 38,730 shares of common stock on June 24, 2026, following the exercise of stock options. The filing indicates that Morgan Stanley Smith Barney LLC will act as the broker/dealer for this transaction. It also discloses previous 10b5-1 sales by SUNG LEE on May 5, 2026, amounting to 23,906 shares for $1,837,766.45.
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK)
Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (CYTK), sold 3,500 shares of the company on June 23, 2026. This transaction brings his total holdings to 153,902 shares. Over the past year, Malik has sold 61,940 shares with no purchases, and the stock is considered a "Possible Value Trap" based on its GF Value, with a price-to-GF-Value ratio of 0.32.
Form 4 Cytokinetics Inc For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Cytokinetics Inc. dated June 23. It provides no further details about the filing but includes general market information, indices, commodity prices, and trending stocks. The content primarily serves as a news headline with links to broader financial data.
CYTOKINETICS (CYTK) EVP Malik exercises options, sells 3,500 shares, keeps large stake
CYTOKINETICS EVP of Research & Development Fady Ibraham Malik exercised options to acquire 3,500 shares of common stock at $7.80 per share and subsequently sold the same number of shares at an average price of $79.51 per share. Despite this sale, Malik retains a substantial holding of 153,902 common shares and 40,886 non-qualified stock options. This transaction is characterized as routine portfolio management, not a significant change in insider positioning.
Cytokinetics Stock Rockets 18% With 7-Day Winning Streak
Cytokinetics stock experienced a significant surge, rocketing 18% and extending its winning streak to seven days. The article title highlights this impressive short-term performance for the company's shares.
Cytokinetics Stock Surges 18%, With A 7-Day Winning Spree
Cytokinetics (CYTK) stock experienced an 18% surge over a 7-day winning streak, increasing its market capitalization by $1.5 billion to $9.8 billion. Despite this recent gain, the article highlights the stock's "Very High valuation" and classifies it as "Unattractive" due to "Moderate operating performance and financial condition." It also provides historical return data for CYTK compared to the S&P 500 and lists key financial metrics for the company.
Cytokinetics stock reaches 52-week high at 80.25 USD
Cytokinetics (CYTK) stock reached a 52-week high of $80.25, trading near its peak at $79.97 with a market capitalization of $10.88 billion after a 144.91% increase over the past year. This growth is attributed to strategic initiatives, drug development advancements, and significant revenue growth, despite an InvestingPro analysis suggesting potential overvaluation. Recent developments include a successful stock offering, the European launch of its heart drug Myqorzo, and reaffirmed Outperform ratings from analysts.
Cytokinetics (CYTK) RBC Capital Markets Global Healthcare Conference 2026 Summary
This article summarizes Cytokinetics' (CYTK) presentation at the RBC Capital Markets Global Healthcare Conference 2026. Key highlights include the strong commercial performance of MYKORZO, exceeding launch expectations with high physician awareness and persistency rates. The company is actively pursuing expanding payer access, international market penetration into Europe and Japan, and advancing its pipeline with regulatory updates for MAPLE-HCM sNDA and positive ACACIA-HCM trial results for nHCM.
Cytokinetics Stock 6-Day Winning Spree: Stock Climbs 17%
Cytokinetics (CYTK) has experienced a 6-day winning streak, with its stock climbing 17% and its market capitalization increasing by $1.4 billion to $9.7 billion. Despite this surge, T
Cytokinetics (CYTK) Is Up 12.3% After Myqorzo Wins US and EU Approvals and Launches – What's Changed
Cytokinetics (CYTK) has transitioned to a commercial-stage biotech after Myqorzo, its therapy for obstructive hypertrophic cardiomyopathy, received FDA and European Commission approvals and launched in the U.S. This shift means the company will now focus on product uptake, reimbursement, and regional rollouts, impacting its operating profile and risk. Analysts project significant revenue growth and a substantial increase in earnings by 2029 for Cytokinetics.
Certain Options of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 21-JUN-2026.
Certain options of Cytokinetics, Incorporated are under a lock-up agreement set to expire on June 21, 2026. This lock-up period for directors and executive officers spans 45 days, from May 6, 2026, to June 21, 2026, during which they cannot sell shares without underwriter consent. The agreement involves Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, and J.P. Morgan Securities LLC.
Cytokinetics (CYTK) Stock Could Be 15% Undervalued After Myqorzo Approval
Cytokinetics (CYTK) stock is considered 15% undervalued after its first commercial product, Myqorzo, received FDA approval for symptomatic obstructive hypertrophic cardiomyopathy. Despite strong short-term stock performance and a significant discount to analyst targets, the company's valuation is driven by rapid revenue expansion and potential future growth from its pipeline and muscle biology platform. Investors are encouraged to review the company's financials for potential risks and rewards.
Cytokinetics stock rating reaffirmed at Outperform by RBC Capital
RBC Capital has reaffirmed its Outperform rating for Cytokinetics (NASDAQ: CYTK) with a $119.00 price target, anticipating a stock rebound following the release of trial 7500 data. The firm believes the stock is undervalued despite its recent strong performance, including a 12% gain weekly and 131% annually. RBC Capital also noted the company's significant progress, including the launch of its heart drug Myqorzo in Germany and a successful $805 million stock offering.
Cytokinetics Inc (CYTK) Earnings Forecast: Future EPS & Revenue Growth Estimates
Cytokinetics Inc (CYTK) currently has an earnings forecast score of 8.09, ranking 162nd in its industry. Analysts, based on 22 ratings, forecast an average price target of $79.00, with a strong buy trend. The company's expected revenue for the next quarter is $17.31 million, and EPS is projected at -$1.67.
Cytokinetics grants stock, RSUs and PSUs to 12 new employees
Cytokinetics (Nasdaq: CYTK) announced inducement equity awards to 12 new employees on June 15, 2026, under Nasdaq Listing Rule 5635(c)(4). The grants include stock options for 24,784 shares with an exercise price of $71.38, 16,429 Restricted Stock Units (RSUs), and 2,242 Performance Stock Units (PSUs). These awards are subject to multi-year vesting schedules and continued service, aligning with the company's 2004 Equity Incentive Plan.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics announced inducement grants under Nasdaq Listing Rule 5635(C)(4). The article is a very brief news item from Refinitiv, indicating this information as part of their corporate disclosures. No further details about the grants are provided within this content.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics, Incorporated announced inducement grants of stock options, restricted stock units (RSUs), and performance stock units (PSUs) to 12 new employees in May and June 2026, as a material inducement for their employment. These awards were granted under Nasdaq Listing Rule 5635(c)(4), with specific vesting schedules for each type of grant. The company also provided an overview of its focus on cardiovascular biopharmaceuticals and pipeline, including MYQORZO® (aficamten) and investigational medicines omecamtiv mecarbil and ulacamten.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics, Incorporated announced the grant of stock options, restricted stock units (RSUs), and performance stock units (PSUs) to 12 new employees in May and June 2026. These grants, totaling 24,784 shares in stock options, 16,429 RSUs, and 2,242 PSUs, serve as material inducements for their employment. The awards are subject to vesting schedules and performance goals, adhering to Nasdaq Listing Rule 5635(c)(4).
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
Cytokinetics (CYTK) has seen an 18.4% year-to-date gain, driven by the FDA approval and strong initial launch of its first commercial product, Myqorzo, for obstructive hypertrophic cardiomyopathy (oHCM). The company is expanding Myqorzo's market with European approval and is pursuing label expansion, while also advancing other pipeline candidates. Despite competition from Bristol Myers Squibb's Camzyos, Myqorzo's sustained commercial traction is crucial for Cytokinetics' long-term valuation.
Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short
Edgewise Therapeutics' investigational drug EDG-7500 for hypertrophic cardiomyopathy showed mixed results in its Phase 2 CIRRUS-HCM trial, leading to a stock dip despite analysts calling the safety profile "excellent." While the drug improved outcomes in obstructive hypertrophic cardiomyopathy (oHCM), its performance in non-obstructive hypertrophic cardiomyopathy (nHCM) underwhelmed investors when compared to competitors like Cytokinetics' Myqorzo. However, its potential to be a "REMS-less" HCM drug could make it a preferred option.
Cytokinetics shares climb as investors refocus on MYQORZO launch momentum and expansion runway
Cytokinetics (CYTK) shares rose by 6.5%, driven by renewed investor optimism regarding the commercial launch of MYQORZO (aficamten) and its potential for market expansion. This positive sentiment follows recent positive Phase 3 results for aficamten in non-obstructive hypertrophic cardiomyopathy and the initiation of its first commercial European launch in Germany. The article also details recent insider trading activity, significant institutional holding changes, and current analyst ratings and price targets for CYTK.
Edgewise heart drug passes key trial test
Edgewise Therapeutics announced positive Phase 2 clinical trial results for its experimental heart disease drug, EDG-7500, showing it reduced disease signs and biological markers in cardiomyopathy patients. The drug will advance to pivotal studies. Despite these positive outcomes, the company's shares fell due to high investor expectations, though analysts viewed the data positively, noting the drug's impressive safety profile and efficacy compared to competitors.
Cytokinetics (Nasdaq:CYTK) - Stock Analysis
Cytokinetics (Nasdaq:CYTK) is a biopharmaceutical company focused on developing treatments for debilitating diseases, primarily hypertrophic cardiomyopathy (HCM). The company's drug MYQORZO (aficamten) has received regulatory approvals in the U.S., China, and the EU for obstructive HCM, with commercial launch tracking ahead of expectations. Despite its promising drug pipeline and recent positive clinical trial data, the company faces financial challenges, including ongoing losses, significant insider selling, and negative shareholder equity.
Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares in open market trade
Cytokinetics (CYTK) CEO Robert I. Blum sold 7,500 shares of common stock at $70.46 per share in an open market transaction. Following this sale, Blum directly holds 385,330 shares, with additional indirect holdings through two irrevocable trusts. The transaction, reported in a Form 4 SEC filing, represents a net sale of $528,450.
